Furthermore, assessing the feasibility of treating alveolar bone resorption in obese patients with periodontitis using RBP4/visfatin monoclonal antibodies or blockers lays the groundwork for long-term clinical transformation and precise treatment. Here, RBP4 is linked to periodontitis.